How Can Smart Cities Elevate Cybersecurity Efforts?

 

Striking a balance on cybersecurity in smart cities is tough. It falls somewhere between implementing connected technology that is interoperable enough to be functional and not so open source that it’s open for vulnerabilities.

On this episode of MarketScale TV, live from the MarketScale Tradeshow Booth, Voice of B2B Daniel Litwin talked with Paul Doherty, President, and CEO, of the Digit Group, a smart city solution provider giving solutions on everything from master planning and architectural design services to real-world implementations of blockchain and IoT solutions.

There have been a lot of enterprise companies across many industries getting hit with new ransomware and malware attacks. Regardless, it seems, at least anecdotally, that cyber-attacks are on the rise or at least high-profile ones. When cities are building out their digital networks, it’s essential to prioritize cybersecurity, considering the recent attacks and analyzing which threats should be taken seriously.

“It’s a package that, depending on the threat, you have a certain protocol that’s part how you build it out, to begin with from an architecture and design aspect of what that stack looks like, what the APIs look like,” Doherty said. “Along with behavior change of reaction, resilience, which ultimately leads to getting out in front of the problem.”

The digital world that Doherty is referring to had to be built with different protocols in mind on where they thought the attacks were going to occur. Of course, once you do this, the attacks tend to appear somewhere else. Therefore, it’s crucial to build machine learning and AI to constantly look for those bad actors.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More